Trial
NCT04303858
A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Solid Tumors
Intervention
Eciskafusp Alfa
Why stopped
After risk/benefit analysis, there was a very low probability (4.4%) of meeting the prespecified gating criteria for the Objective Response Rate at the final analysis.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-02